REVIEW

Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies [version 1; peer review: 2 approved]

Ladislav Senolt

Department of Rheumatology, First Faculty of Medicine, Charles University, Institute of Rheumatology, Prague, Czech Republic, 128 50, Czech Republic

V1 First published: 30 Aug 2019, 8(F1000 Faculty Rev):1549
<https://doi.org/10.12688/f1000research.18688.1>

Latest published: 30 Aug 2019, 8(F1000 Faculty Rev):1549
<https://doi.org/10.12688/f1000research.18688.1>

Abstract

Advances in the treatment of rheumatoid arthritis (RA) are attributed to several aspects such as new classification criteria enabling early diagnosis and intensive treatment with the application of treat-to-target principles as well as better understanding of the pathogenesis of RA contributing to the development of targeted therapies. However, reaching remission is still not achieved in most patients with RA, which is one of the driving forces behind the continuous development of novel therapies and the optimization of therapeutic strategies. This review will outline several new therapeutic antibodies modulating anti-inflammatory cytokines interleukin (IL)-2 and IL-10 and pro-inflammatory mediators granulocyte-macrophage colony-stimulating factor, fractalkine, and IL-6 that are in various stages of clinical development as well as the progress in manufacturing biotechnologies contributing to the next generation of antibodies and their potential to expand the therapeutic armamentarium for RA. In addition, the fate of unsuccessful therapies including agents targeting IL-15, the IL-20 family, IL-21, chemokine CXCL10, B-cell activating factor (BAFF), and regulatory T (Treg) cells or a novel concept targeting synovial fibroblasts via cadherin-11 will be discussed.

Keywords

rheumatoid arthritis, biological therapies, monoclonal antibodies, therapeutic strategies

Open Peer Review

Approval Status

	1	2
version 1 30 Aug 2019

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Diego Kyburz**, University Hospital Basel, Basel, Switzerland
2. **John Isaacs**, Newcastle University, Newcastle upon Tyne, UK

Any comments on the article can be found at the end of the article.

Corresponding author: Ladislav Senolt (seno@revma.cz)

Author roles: Senolt L: Conceptualization, Resources, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: Ladislav Senolt has been involved in clinical trials or had lectures related to the following companies: AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Merck Sharp and Dohme, Mylan, Novartis, Pfizer, Roche, Takeda and UCB.

Grant information: This work was supported by the Project for Conceptual Development for the institution of Ministry of Health Czech Republic - Institute of Rheumatology (number 023728).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Senolt L. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Senolt L. **Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies [version 1; peer review: 2 approved]** F1000Research 2019, 8(F1000 Faculty Rev):1549 <https://doi.org/10.12688/f1000research.18688.1>

First published: 30 Aug 2019, 8(F1000 Faculty Rev):1549 <https://doi.org/10.12688/f1000research.18688.1>

Introduction

In recent years, dramatic advances have emerged across medical disciplines in understanding the pathogenesis of immune-mediated inflammatory diseases, which are accompanied by a significant shift in treatment options¹. One of the most significant advances has been shown in the treatment of rheumatoid arthritis (RA), in which the discovery of glucocorticoid activity was among the first therapeutic milestones in the 1950s², followed by widespread use of methotrexate since the turn of the 1980s and 1990s³. Later on, success in the treatment of RA can be attributed to the introduction of new classification criteria allowing earlier diagnosis and treatment and application of the treat-to-target principles with the aim to induce remission or at least low disease activity⁴⁻⁶. The biggest breakthrough in the treatment of RA, however, comes with biologic therapy, which has gradually begun to spread since the beginning of the new millennium with the introduction of tumor necrosis factor (TNF) inhibitors into clinical practice⁷.

Targeted disease-modifying antirheumatic drugs (DMARDs), consisting of biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs), antagonize soluble cytokines and their receptors and directly affect immune cell activity or intracellular signaling pathways⁸⁻¹⁰. The effect of targeted therapies is relatively rapid and often accompanied by a significant suppression of inflammation. In most cases, it can substantially improve quality of life and stop or significantly slow the progression of functional and structural impairment¹¹. Currently, out of the biological therapies, five original TNF inhibitors and already even more biosimilar TNF inhibitors, two interleukin-6 receptor (IL-6R) inhibitors, and one IL-1 receptor inhibitor as well as B-lymphocyte (CD20) and co-stimulatory signal (CD28-B7 interaction) for T-cell activation inhibitors are available for the treatment of RA (Table 1). In addition to bDMARDs, two tsDMARDs, including Janus kinase inhibitors (JAKi) tofacitinib (pan-JAKi) and baricitinib (JAK1/2i) (Table 1), have expanded the treatment armamentarium¹².

Table 1. Currently approved targeted therapies for rheumatoid arthritis

Original biologic DMARDs		Target	Structure		
Infliximab (3–5 mg i.v. every 8 weeks)		TNF	Chimeric mAb		
Adalimumab (40 mg s.c. every other week)		TNF	Human mAb		
Etanercept (50 mg s.c. every week)		TNF	Fc fusion protein		
Golimumab (50 mg s.c. once a month)		TNF	Human mAb		
Certolizumab pegol (200 mg s.c. every other week)		TNF	Humanized PEGylated Fab fragment		
Rituximab (1,000 mg i.v. every 6 months)		CD20 (B-cells)	Chimeric mAb		
Abatacept (125 mg s.c. every week)		CD80/86 (costimulation)	Fc fusion protein		
Tocilizumab (162 mg s.c. every week)		IL-6R	Humanized mAb		
Sarilumab (150–200 mg s.c. every other week)		IL-6R	Human mAb		
Targeted synthetic DMARDs		Target	Structure		
Tofacitinib (10 mg daily)		JAK1, JAK2, JAK3	Small molecule		
Baricitinib (2–4 mg daily)		JAK1, JAK2	Small molecule		
Biosimilar DMARDs	Target	Reference product	Approved by EMA/FDA	Manufacturer	
Remsima/Inflectra (CT-P13)	TNF	Infliximab	2013/2016	Celltrion	
Flixabi/Renflexis (SB2)	TNF	Infliximab	2016/2017	Samsung Bioepis/Biogen	
Zessly/Ifixi (GP1111/PF-06438179)	TNF	Infliximab	2018/2017	Sandoz (EU)/Pfizer (US)	
Amgevita/Amjevita (ABP 501)	TNF	Adalimumab	2017/2016	Amgen	
Cyltezo (BI 695501)	TNF	Adalimumab	2017/2017	Boehringer Ingelheim	
Imraldi (SB5)	TNF	Adalimumab	2017/*	Samsung Bioepis/Biogen	
Hyrmoz (GP2017)	TNF	Adalimumab	2018/2018	Sandoz	
Hulio (MYL-1401A)	TNF	Adalimumab	2018/2018	Mylan	
Benepali (SB4)	TNF	Etanercept	2016/*	Samsung Bioepis/Biogen	
Erelzi (GP2015)	TNF	Etanercept	2017/2016	Sandoz	
Truxima (CT P10)	CD20	Rituximab	2017/2018	Celltrion/Hospira (Pfizer)	
Rixathon	CD20	Rituximab	2017	Sandoz (EU)	

CD, cluster of differentiation; DMARDs, disease-modifying antirheumatic drugs; EMA, European Medicines Agency; FDA, US Food and Drug Administration; IL, interleukin; IL-6R, interleukin-6 receptor; i.v., intravenously; JAK, Janus kinase; mAb, monoclonal antibody; s.c., subcutaneously; TNF, tumor necrosis factor

*accepted for review by FDA, assessed 19 March 2019.

Although the fate of patients with RA has improved significantly and a milder course of disease can be observed than in the past¹³, persistent remission, let alone drug-free remission or complete cure, is still elusive¹⁴. This review will outline several new directions for the potential new therapeutic antibodies and treatment strategies for RA, new biological drugs against new targets, and biological drugs against already-known targets that are currently in early or late stages of clinical development.

Cytokine and cell-targeted therapies

The development of biological therapies for RA has been facilitated by two main assumptions. The first prerequisite is an increasing understanding of the pathophysiological processes in which systemic immune mediators, immune cells, and signaling pathways play a role and have become targets for specific immune interventions¹⁵. The second important assumption is the dynamic development of the pharmaceutical industry and advances in genetic engineering and biotechnology¹⁶. Potential therapeutic antibodies that are in various stages of clinical development are summarized in **Figure 1**.

New targets in later phases of development

Granulocyte-macrophage colony-stimulating factor

Granulocyte-macrophage colony-stimulating factor (GM-CSF) was first described in the 1970s and is considered a

pro-inflammatory cytokine, which is upregulated upon stimulation with multiple mediators such as lipopolysaccharide (LPS) or TNF and is produced by a variety of immune as well as resident tissue cells¹⁷. As the expression of GM-CSF is increased in the synovial tissue and synovial fluid of patients with RA, it can stimulate the synthesis of adhesion molecules and pro-inflammatory cytokines, and it can also activate synovial fibroblasts and polarize macrophages into an inflammatory M1 phenotype, thus promoting rheumatoid synovial inflammation¹⁸. At present, several monoclonal antibodies targeting the GM-CSF pathway in patients with RA are being studied¹⁹.

Mavrilimumab (CAM-3001), a monoclonal antibody against GM-CSF receptor alpha being developed by MedImmune, has been extensively evaluated in the EARTH development program^{20,21}. Mavrilimumab was administered in a phase II dose-ranging study (10–100 mg) every other week for a total of 12 weeks to patients with active RA on background methotrexate²⁰. The primary endpoint was met: the greater proportion of patients receiving mavrilimumab compared with placebo achieved a ≥ 1.2 decrease in disease activity score (DAS28-CRP) from baseline at week 12 (55.7% versus 34.7%; $p=0.003$). The 100 mg dose demonstrated a significant effect versus placebo on DAS28-CRP < 2.6 (23.1% versus 6.7%, $p=0.016$). In a phase IIb study in RA patients with inadequate

Figure 1. Potential biological therapies for the management of rheumatoid arthritis that are currently in various stages of clinical development. Black text shows therapies that were effective in the treatment of rheumatoid arthritis, although some of the drugs are not further evaluated in rheumatoid arthritis owing to company prioritization. White text shows therapies that failed to prove efficacy or whose clinical trials were terminated owing to safety concerns. *However, anti-CD20 monoclonal antibody such as rituximab is effective and licensed for the treatment of rheumatoid arthritis. BAFF, B-cell activating factor; CXCL, C-X-C motif ligand; GM-CSF, granulocyte-macrophage colony-stimulating factor; GM-CSFR, granulocyte-macrophage colony-stimulating factor receptor; IL, interleukin; mAb, monoclonal antibody; TNF, tumor necrosis factor; Treg, T regulatory

response to at least one conventional synthetic DMARD (csDMARD), significantly more mavrilimumab-treated (150, 100, and 30 mg) patients achieved American College of Rheumatology definition of improvement (ACR20) compared with placebo at week 24 (73.4%, 61.2%, 50.6% versus 24.7%, respectively [$p<0.001$]) and clinically meaningful response was observed as early as one week after treatment initiation²¹. Another phase IIb study evaluated the efficacy and safety of mavrilimumab and golimumab (anti-TNF) in patients with RA who have had an inadequate response to csDMARDs and anti-TNF agents²². Mavrilimumab demonstrated numerically lower response rates compared with golimumab in patients with inadequate response to csDMARDs and similar efficacy to that of golimumab in the anti-TNF non-responders. However, the study was not powered to provide a direct comparison between mavrilimumab and golimumab, and it is probable that a suboptimal dosage of mavrilimumab was used (100 mg every other week)²². Pulmonary safety assessments were performed because the inhibition of GM-CSF signaling has the potential to affect the clearance of surfactant by alveolar macrophages and thus be responsible for pulmonary alveolar proteinosis. Although there was a potential risk of this rare disease, including neutropenia, infections, and other lung toxicities associated with the blockade of GM-CSF, none of these studies nor a long-term extension study up to 3.3 years revealed such concerns²³. Mavrilimumab demonstrated sustained efficacy and an acceptable safety profile; however, due to future clinical development plans, the study was terminated (ClinicalTrials.gov Identifier: NCT01712399).

Otilimab (GSK 3196165 or MOR103) is a fully human high-affinity IgG monoclonal antibody against GM-CSF being developed by GlaxoSmithKline. In a phase IIb dose-ranging study (BAROQUE), patients with active RA were randomized to placebo or otilimab (22.5, 45, 90, 135, or 180 mg) administered weekly for five injections, and then every other week until week 50²⁴. Dose-related treatment effect with the onset of clinical response as early as week one was observed for all doses. However, the primary endpoint (DAS28 remission at week 24) was not achieved; it was only numerically higher in patients at the highest dose of otilimab versus placebo (16% versus 3%; $p=0.134$). In addition, exposure to otilimab was lower than predicted owing to increased apparent clearance. In July 2019, a phase III clinical program ("ContraSt") was announced, in which otilimab (90 and 150 mg weekly doses) will be compared with two treatments with different modes of action: JAKi (tofacitinib) and anti-IL-6R (sarilumab) (<https://www.gsk.com>).

Namilumab (MT203), lenzilumab (KB003), and gimsilumab (MORAb-022) being developed by Takeda, KaloBios Pharmaceuticals, and Morphotek, respectively, are fully human IgG1 monoclonal antibodies against GM-CSF. While initial studies, at least with namilumab²⁵, demonstrated good safety and promising efficacy data, no further results from phase II studies have been reported so far¹⁹. In addition, based on

negative results from a psoriasis study²⁶ and results from a proof-of-concept study in RA (ClinicalTrials.gov Identifier: NCT02393378), further studies on namilumab in psoriasis and RA were terminated.

Interestingly, GM-CSF-targeting therapies are also being studied in other rheumatic diseases. For instance, otilimab was studied in patients with hand osteoarthritis and showed numerical reduction in pain and functional impairment, while little difference was observed with placebo on tender and swollen joints, including magnetic resonance imaging (MRI) endpoints²⁷. In patients with axial spondyloarthritis, a phase IIa proof-of-concept study evaluating the safety and efficacy of namilumab has been recruiting subjects since August 2018 (ClinicalTrials.gov Identifier: NCT03622658).

Old targets with the focus on interleukin-6

In mid-2017, sarilumab (trade name Kevzara), a human monoclonal antibody against IL-6R, was approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of RA. Sarilumab showed significantly greater affinity to recombinant human IL-6R compared with tocilizumab and longer half-life with a similar safety profile^{28,29}. Further biological drugs targeting IL-6 pathways are in development.

Clazakizumab (formerly ALD518 and BMS-945429) is a humanized monoclonal antibody against IL-6. In a phase IIb study³⁰, the primary endpoint was met; ACR20 response rates at week 12 were greater for clazakizumab (25, 100, and 200 mg) once monthly in combination with methotrexate (MTX) or clazakizumab monotherapy (100 and 200 mg) versus MTX (76.3%, 73.3% and 60.0% or 55.0% and 61.0% versus 39.3%; $p<0.05$). Also, remission rates as assessed by DAS28-CRP for clazakizumab plus MTX were greater than for MTX plus original adalimumab (40.0–49.2% versus 23.7%). The treatment was well tolerated with no unanticipated safety signals, consistent with the known pharmacologic effects of IL-6 blockade. Bristol-Myers Squibb has decided, based on portfolio prioritization, to return worldwide rights to clazakizumab to Alder BioPharmaceuticals. However, no further trials in RA are ongoing. The drug is currently in the early phases of development for the treatment of kidney transplant recipients with late antibody-mediated rejection (ClinicalTrials.gov Identifier: NCT03380377 and NCT03380962).

Olokizumab (CDP6038), a humanized monoclonal antibody against IL-6, was formerly developed by UCB Pharma and out-licensed to R-Pharm in 2013. In a phase IIb study, the primary endpoint was met; patients with active RA who had previously failed TNF inhibitor therapy demonstrated a significant decrease in DAS28-CRP at week 12 for all doses (60 mg, 120 mg, and 240 mg) administered every four or every two weeks with results comparable to tocilizumab³¹. Safety data were consistent with the use of IL-6-targeted therapy. Although no further results have been reported, phase III studies (CREDO) are either completed

(ClinicalTrials.gov Identifier: NCT02760368, NCT02760433) or ongoing (ClinicalTrials.gov Identifier: NCT02760407, NCT03120949).

Sirukumab (CNTO-136; proposed trade name Plivensia), a human monoclonal antibody against IL-6, was developed by Centocor, GlaxoSmithKline, and Janssen Biotech. Sirukumab was investigated at doses of 100 mg and 50 mg every two and four weeks, respectively, in five phase III trials (SIRROUND) in a broad spectrum of patients with RA³². Sirukumab showed significant improvements in disease activity, physical function, and quality of life along with inhibition of radiographic progression^{33,34}. In a head-to-head study with adalimumab, sirukumab monotherapy showed greater improvements in disease activity (DAS28) but similar ACR50 response rates at week 24³⁵. Although the long-term safety of sirukumab seems to be similar to that of other IL-6-inhibiting agents, drug regulatory authorities suggested re-evaluating the safety profile of sirukumab for increased mortality rates in post open-label studies³². Interestingly, the drug is currently under development for the treatment of major depressive disorder (ClinicalTrials.gov Identifier: NCT02473289).

New targets in early phases of development

Interleukin-2

IL-2, first cloned in the early 1980s, is predominantly produced by CD4⁺ T-cells and activated dendritic cells and has pleiotropic functions (for review, see 36). In high doses, IL-2 has been found to promote effector T cells, whereas low-dose IL-2 (ld-IL2) activates regulatory T cells (Tregs) and thus can have a broad therapeutic potential in many autoimmune and inflammatory diseases. Indeed, the results of a first prospective, phase I–IIa clinical trial recently demonstrated that ld-IL2 (1,000,000 IU/day) given for five days and then once every other week for six months selectively activated and expanded Tregs without activating effector T cells. Furthermore, the authors reported signals of efficacy without safety issues in 46 patients across 11 autoimmune and inflammatory chronic diseases, including RA, ankylosing spondylitis, systemic lupus erythematosus (SLE), and psoriasis³⁷. In addition, *in vitro* and first-in-human data on a fusion protein of IL-2 mutein and human Fc (AMG 592) demonstrated dose-dependent, selective expansion of Tregs with no increase of major pro-inflammatory cytokines such as IL-6, TNF, or interferon- γ (IFN- γ) in healthy volunteers³⁸. Based on these data, another phase Ib/IIa study evaluating the safety and efficacy of AMG 592 has been underway in patients with RA since May 2018 (ClinicalTrials.gov Identifier: NCT03410056) but also in patients with SLE (ClinicalTrials.gov Identifier: NCT03451422).

Interleukin-10

IL-10 is produced by virtually all leukocytes and inhibits the production of pro-inflammatory cytokines, e.g. TNF and IFN- γ , and abrogates antigen presentation and cell proliferation (for review, see 39). Despite the fact that it belongs to the most potent anti-inflammatory cytokine, limited efficacy with subcutaneously administered recombinant IL-10 was observed in a phase I trial in patients with RA in the past⁴⁰.

Several reasons for this discrepancy can be speculated, e.g. complex mechanism of pathophysiological action of IL-10, including potential pro-inflammatory activity⁴¹, or short half-life of IL-10 hampering effective delivery of recombinant IL-10 to the sites of inflammation. To overcome these obstacles, Dekavil (F8IL10), a fully human anti-inflammatory immunocytokine composed of the vascular-targeting anti-fibronectin domain fused to IL-10, is under investigation in patients with RA⁴². In a phase II clinical trial, Dekavil (30–600 mg/kg) is administered once a week for eight consecutive weeks by subcutaneous injection in combination with MTX to RA patients who have previously failed at least one TNF inhibitor. Preliminary data have demonstrated some signs of efficacy, with 46% demonstrating ACR20 clinical response after eight weeks of drug administration. Dekavil was well tolerated; however, mild injection site reaction occurred in 60% of the patients⁴³.

Fractalkine

Fractalkine (FKN) is known as a CX3C chemokine that promotes cell adhesion and chemotaxis, but also angiogenesis and osteoclastogenesis, and increases the production of inflammatory mediators, thus playing a significant role in the pathogenesis of RA (reviewed in 44). Recently, first data from a phase II, multicenter, randomized, double-blind, placebo-controlled study with anti-FKN monoclonal antibody (E6011) in patients with active RA were released⁴⁵. This novel approach targeting FKN demonstrated reliable safety and promising efficacy with a dose-dependent clinical response, particularly in patients who showed higher baseline CD16⁺ monocytes (ACR20 at week 24: 30% for placebo, 46.7% for 100 mg, 57.7% for 200 mg, and 69.6% for 400/200 mg).

Unsuccessful biological therapies in rheumatoid arthritis

Although several pro-inflammatory cytokines play a significant role in the pathogenesis of RA and their inhibition contributed to a significant reduction in synovial inflammation and joint damage in an experimental model of arthritis and proved to be effective in early phases of development in humans, further studies failed to confirm significant efficacy⁴⁶ (Table 2). For instance, IL-1 inhibitors are approved but only modestly effective in RA while highly effective in several autoinflammatory diseases⁴⁷. An early phase study with IL-15 inhibitor therapy seemed to be efficient⁴⁸, but a phase II clinical trial of a fully human monoclonal antibody against IL-15 failed to confirm significant efficacy (ClinicalTrials.gov Identifier: NCT00433875). Although targeting the IL-23/17 axis is effective in spondyloarthritis⁴⁹, strategies to block the IL-17 pathway, IL-12/23 p40, or IL-23 did not prove to be effective in patients with established RA, and the clinical research programs in RA were discontinued⁵⁰. Similarly, the IL-20 family of cytokines such as IL-20 and IL-22 play a significant role in the process of immune cell activation and bone destruction, and although an early phase trial with the IL-20 inhibitor fletikumab was well tolerated and effective, particularly in patients with seropositive RA, further studies with fletikumab and also IL-22 inhibitor fezakinumab were completed several years ago with negative or no final results released^{51,52}. Although IL-21

Table 2. Selected unsuccessful biological therapies in rheumatoid arthritis

Drug	Target	Reason for failure	Citation
HuMax-IL15 (anti-IL-15 mAb)	IL-15	Lack of efficacy	*
Brodalumab (anti-IL-17R mAb)	IL-17	Lack of efficacy	50
Secukinumab (anti-IL-17A mAb)	IL-17	Lack of efficacy	50
Ixekizumab (anti-IL-17A mAb)	IL-17	Lack of efficacy	50
Bimekizumab (dual anti-IL-17A/F mAb)	IL-17	Lack of efficacy	50
Ustekinumab (anti-IL-12/23p40mAb)	IL-12/IL-23	Lack of efficacy	50
Guselkumab (anti-IL-23 mAb)	IL-23	Lack of efficacy	50
Remtolumab (dual anti-TNF/IL-17A)	TNF/IL-17	Not higher efficacy than adalimumab	67
NNC0114 (anti-IL-21 mAb)	IL-21	No final results released	+
Fletikumab (anti-IL-20 mAb)	IL-20	Lack of efficacy	51
Fezakinumab (anti-IL-22 mAb)	IL-22	Negative or no final results released	51
Eldelumab (anti-CXCL10 mAb)	CXCL10	Effective/safe, but no final results released	53
Mavrilimumab (anti-GM-CSFR α)	GM-CSFR α	Effective/safe, terminated (sponsor decision)	ϕ
Namilumab (anti-GM-CSF)	GM-CSF	Lack of efficacy	#
Tabalumab (anti-BAFF)	BAFF	Lack of efficacy	56
Belimumab (anti-BAFF)	BAFF	Terminated (sponsor decision)	±
Ocrelizumab (anti-CD20 mAb)	B-cells	Risk/benefit consideration	54
Ofatumumab (anti-CD20 mAb)	B-cells	Risk/benefit consideration	54
SBI-087 (CD20-targeted SMIP)	B-cells	Further development terminated	55
Alemtuzumab (anti-CD52 mAb)	T-cells	Safety	57
Keliximab (anti-CD4 mAb)	T-cells	Safety	57
Clenoliximab (anti-CD4 mAb)	T-cells	Safety	57
Tregalizumab (anti-CD4 mAb)	Treg cells	Lack of efficacy	58
RG6125 (anti-cadherin-11 mAb)	Cadherin-11	Lack of efficacy	59

BAFF, B-cell activating factor; CXCL, chemokine C-X-C motif ligand; GM-CSFR α , granulocyte-macrophage colony-stimulating factor receptor α ; IL, interleukin; mAb, monoclonal antibody; SMIP, Small Modular ImmunoPharmaceutical; TNF, tumor necrosis factor; Treg, T regulatory

* ClinicalTrials.gov Identifier: NCT00433875

+ ClinicalTrials.gov Identifier: NCT01208506

ϕ ClinicalTrials.gov Identifier: NCT01712399

ClinicalTrials.gov Identifier: NCT03622658

± ClinicalTrials.gov Identifier: NCT00583557

plays an important role in the activation of the immune system, an early phase first-in-man trial with an IL-21 inhibitor (NNC0114-0000-0005) in patients with RA and healthy subjects was finished in 2012 and no further results have been released (ClinicalTrials.gov Identifier: NCT01208506). The first study demonstrating good safety and clinical efficacy of a chemokine inhibitor in patients with RA evaluated eldelumab (MDX-1100), a fully human anti-CXCL10 (anti-IP-10) monoclonal antibody⁵³; however, no further data were released.

Several strategies to inhibit B-cells were tested; for instance, humanized and human monoclonal antibodies ocrelizumab (trade

name Ocrevus) and ofatumumab (trade name Arzerra) proved to be effective in patients with RA. However, after risk/benefit consideration, further studies were discontinued⁵⁴. In order to reduce the molecule, promote penetration to sites of inflammation, and improve efficacy, single-chain antibody polypeptides known as SMIPs (small modular immunopharmaceuticals) have been developed that are approximately one-half to one-third of the size of the standard monoclonal antibody. A next-generation, humanized SMIP protein therapeutic against the CD20 antigen (SBI-087) was evaluated in patients with RA, but further development was terminated⁵⁵. In addition, a further strategy to inhibit B-cell differentiation and survival via

anti-B-cell activating factor (anti-BAFF) antibody has also failed in the treatment of patients with RA⁵⁶. Direct T-cell-targeting therapies such as alemtuzumab, keliximab, and clenoliximab did not show satisfactory results and were accompanied by a number of serious adverse reactions associated with severe CD4⁺ T-lymphopenia and rash⁵⁷. Tregalizumab (BT-061) is a humanized agonist antibody that selectively activates Treg lymphocytes and was tested as an innovative treatment for RA; however, it also did not show significant clinical benefit⁵⁸.

Recently, a novel approach targeting synovial fibroblasts in RA via the inhibition of cadherin-11 was presented⁵⁹. Although an interesting concept, anti-cadherin-11 (RG6125) given on top of anti-TNF therapy in patients with active RA failed to be more effective than placebo and the study was discontinued⁵⁹.

Next-generation antibodies

Conventional monoclonal antibodies (e.g. infliximab or adalimumab), Fc fusion proteins (etanercept and abatacept), and one antibody-derived molecule, a PEGylated anti-TNF Fab fragment (certolizumab pegol), are widely used for the treatment of patients with RA. Further advances in antibody engineering have led to the development of so-called next-generation therapeutic antibodies representing antibody fragments, dual/bispecific targeting variants, and immunocytokines^{60–62}. The purpose is to develop antibodies that are smaller, more stable, have higher affinity and improved tissue penetration, and have lower immunogenicity and toxicity than conventional antibodies. For instance, nanobodies are single-domain antibodies that were originally developed after the discovery of camelid antibodies consisting of heavy chain variable domain (lacking the Fc-equivalent region) and can be engineered to bind to two (or even more) different antigens or epitopes on the cell surface, so-called bispecific (even multispecific) antibodies^{61,62}. These antibodies are frequently used to treat cancer. Another therapeutic success was achieved by the development of immunocytokines, a fusion of an antibody and cytokine, which are widely studied as an anticancer therapy⁶³ and should extend cytokine half-life, reduce systemic adverse events, and deliver the cytokine specifically to sites of inflammation as mentioned above (Dekavil or AMG 592).

Belgian biopharmaceutical company Ablynx has developed unique new-generation bispecific therapeutic nanobodies ozoralizumab (ATN-103) and vobarilizumab (ALX0061) for the treatment of RA, the first humanized bispecific nanobodies, which neutralize TNF and IL-6R, respectively, and also bind to human serum albumin to increase the half-life. Ozoralizumab was tested in subcutaneous form at a once-monthly dosing interval in patients with RA and after 12 weeks of treatment, EULAR response was obtained in 97% of patients, an ACR20 response was achieved in 84%, and DAS28 remission was seen in 38% of patients with RA⁶⁴. A phase II study evaluating long-term safety and tolerability was completed in 2012 (ClinicalTrials.gov identifier: NCT01063803), and no further reports of development have been made so far. An early phase study with vobarilizumab demonstrated promising results as

well, with ACR20 response rates of up to 84% and DAS28 remission rates of up to 58%⁶⁵. In addition, in a phase IIb monotherapy study (head-to-head versus tocilizumab) in RA patients⁶⁶, a similar proportion of vobarilizumab-treated patients achieved ACR20 response at week 12 compared with tocilizumab (73–81% versus 78%). Although more patients achieved DAS remission on highest vobarilizumab dose (225 mg every other week), when using more stringent CDAI and SDAI remission criteria, a similar efficacy was obtained in the monotherapy with vobarilizumab (5–10%) and tocilizumab groups (9–11%).

Remtolumab (ABT-122), developed by AbbVie, is another bispecific antibody, a full-length IgG with dual-variable domains (DVD-Ig), targeting two important human cytokines: TNF and IL-17A. Based on a TNF-transgenic mouse model of arthritis, dual inhibition of both cytokines proved to be more effective in suppressing inflammation and bone/cartilage destruction than either cytokine inhibitor alone⁶⁷. However, a phase II trial demonstrated that a strategy of dual inhibition of TNF and IL-17A with remtolumab does not appear to be significantly different from that of TNF inhibition alone with adalimumab in human patients with RA and psoriatic arthritis⁶⁸. In addition to this finding, recent data proved that another DVD-Ig lutikizumab (ABT-981) targeting IL-1 α/β did not improve pain or synovitis in patients with both erosive hand osteoarthritis and knee osteoarthritis^{69,70}.

Conclusion

Biologicals have become an essential part of the therapeutic armamentarium for RA, significantly ameliorating disease activity and improving quality of life. Furthermore, the progress in our understanding of the pathogenesis of RA has significantly contributed to the development of novel intracellular targeted therapies such as JAK inhibitors tofacitinib and baricitinib that have already been implemented in routine clinical practice. Nowadays, more selective JAK inhibitors and other targeted synthetic therapies are in various stages of clinical development in RA, which is beyond the scope of this review and is reported elsewhere^{71,72}. In addition to the development of new therapies, the patent protection of older original biological agents expires and biosimilars have been entering the market within the last few years, thus lowering the price and enabling the treatment of more patients⁷³.

Despite current practice, early and intensive management with the treat-to-target approach, reaching remission is still not achieved in most patients, which is one of the driving forces behind the continuous development of novel therapies and the optimization of therapeutic strategies⁷⁴. Thus, advances in antibody engineering and further therapeutic targets such as neuro-immune modulation, gene therapy, and epigenetic modification are being evaluated in the treatment of RA^{75–77}. In addition, the two main treatment strategies can be potentially applied in the future to improve disease outcome, halt further progression, or even cure the disease either 1) by an induction-maintenance regime with biological therapies administered as early as the

diagnosis is established⁷⁸ or 2) even before clinical arthritis becomes apparent⁷⁹. Currently, several ongoing proof-of-concept trials are testing whether targeting T-cells or B-cells can induce immunological reset and be used to prevent the onset of RA⁸⁰. An advanced study demonstrated that a single infusion of 1,000 mg rituximab significantly delayed the development of arthritis in patients at risk of developing of RA⁸¹. Other treatment approaches for preventive strategies may represent, for instance, the use of tolerogenic dendritic cells⁸² or targeting the IL-17/23 axis⁸³ in order to block arthritis development in pre-clinical phases of the disease. However, further research

is needed to determine which therapeutic agent or strategy would best suit each individual patient.

Grant information

This work was supported by the Project for Conceptual Development for the institution of Ministry of Health Czech Republic - Institute of Rheumatology (number 023728).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Choi JH, Feldman M: **Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies.** *Nat Med.* 2015; 21(7): 730–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hench PS, Kendall EC, Slocumb CH, *et al.*: **The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report.** *Ann Rheum Dis.* 1949; 8(2): 97–104.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Weinblatt ME, Maier AL: **Longterm experience with low dose weekly methotrexate in rheumatoid arthritis.** *J Rheumatol Suppl.* 1990; 22: 33–8.
[PubMed Abstract](#)
- Aletaha D, Neogi T, Silman AJ, *et al.*: **2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.** *Ann Rheum Dis.* 2010; 69(9): 1580–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Felson DT, Smolen JS, Wells G, *et al.*: **American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.** *Ann Rheum Dis.* 2011; 70(3): 404–13.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Smolen JS, Breedveld FC, Burmester GR, *et al.*: **Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.** *Ann Rheum Dis.* 2015; 75(1): 3–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lipsky PE, van der Heijde DM, St Clair EW, *et al.*: **Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.** *N Engl J Med.* 2000; 343(22): 1594–602.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Senolt L, Vencovsky J, Pavelka K, *et al.*: **Prospective new biological therapies for rheumatoid arthritis.** *Autoimmun Rev.* 2009; 9(2): 102–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Buch MH, Emery P: **New therapies in the management of rheumatoid arthritis.** *Curr Opin Rheumatol.* 2011; 23(3): 245–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Burmester GR, Feist E, Dörner T: **Emerging cell and cytokine targets in rheumatoid arthritis.** *Nat Rev Rheumatol.* 2014; 10(2): 77–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Stavre Z, Upchurch K, Kay J, *et al.*: **Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis.** *Curr Rheumatol Rep.* 2016; 18(12): 72.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schwartz DM, Kanno Y, Villarino A, *et al.*: **JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.** *Nat Rev Drug Discov.* 2017; 16(12): 843–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Kievit W, Fransen J, de Waal Malefijt MC, *et al.*: **Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009.** *Rheumatology (Oxford).* 2013; 52(8): 1500–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Aletaha D, Smolen JS: **Achieving Clinical Remission for Patients With Rheumatoid Arthritis.** *JAMA.* 2019; 321(5): 457–458.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Veale DJ, Orr C, Fearon U: **Cellular and molecular perspectives in rheumatoid arthritis.** *Semin Immunopathol.* 2017; 39(4): 343–54.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Azhar A, Ahmad E, Zia Q, *et al.*: **Recent Updates on Molecular Genetic Engineering Approaches and Applications of Human Therapeutic Proteins.** *Curr Protein Pept Sci.* 2017; 18(3): 217–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Burgess AW, Metcalf D: **The nature and action of granulocyte-macrophage colony stimulating factors.** *Blood.* 1980; 56(6): 947–58.
[PubMed Abstract](#)
- Zhou D, Huang C, Lin Z, *et al.*: **Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways.** *Cell Signal.* 2014; 26(2): 192–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Cook AD, Hamilton JA: **Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.** *Ther Adv Musculoskelet Dis.* 2018; 10(2): 29–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Burmester GR, Weinblatt ME, McInnes IB, *et al.*: **Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.** *Ann Rheum Dis.* 2013; 72(9): 1445–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Burmester GR, McInnes IB, Kremer J, *et al.*: **A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.** *Ann Rheum Dis.* 2017; 76(6): 1020–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Weinblatt ME, McInnes IB, Kremer JM, *et al.*: **A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.** *Arthritis Rheumatol.* 2018; 70(1): 49–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Burmester GR, McInnes IB, Kremer JM, *et al.*: **A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.** *Arthritis Rheumatol.* 2018; 70(5): 679–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Buckley C, Simon Campos JA, Yakushin S, *et al.*: **A Phase IIb Dose-ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate (abstract).** *Arthritis Rheumatol.* 2018; 70(suppl 10): abstract number 1938.
[Reference Source](#)
- Huizinga TW, Batalov A, Stoilov R, *et al.*: **Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.** *Arthritis Res Ther.* 2017; 19(1): 53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Papp KA, Gooderham M, Jenkins R, *et al.*: **Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.** *Br J Dermatol.* 2019; 180(6): 1352–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schett G, Bainbridge C, Berkowitz M, *et al.*: **A Phase IIb Study of Anti-GM-CSF Antibody GSK3196165 in Subjects with Inflammatory Hand Osteoarthritis (abstract).** *Arthritis Rheumatol.* 2018; 70(suppl 10): abstract number 1365.
[Reference Source](#)
- Rafique A, Martin J, Blome M, *et al.*: **Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (IL-6R) alpha.** *Ann Rheum Dis.* 2013; 72 (suppl 3): abstract number 797.
[Publisher Full Text](#)

29. **F** Avci AB, Feist E, Burmester GR: **Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?** *BioDrugs*. 2018; **32**(6): 531–46. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
30. Weinblatt ME, Mease P, Mysler E, *et al.*: **The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.** *Arthritis Rheumatol*. 2015; **67**(10): 2591–600. [PubMed Abstract](#) | [Publisher Full Text](#)
31. Genovese MC, Fleischmann R, Furst D, *et al.*: **Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.** *Ann Rheum Dis*. 2014; **73**(9): 1607–15. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Bartoli F, Bae S, Cometi L, *et al.*: **Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018.** *Expert Rev Clin Immunol*. 2018; **14**(7): 539–47. [PubMed Abstract](#) | [Publisher Full Text](#)
33. **F** Aletaha D, Bingham CO 3rd, Tanaka Y, *et al.*: **Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.** *Lancet*. 2017; **389**(10075): 1206–17. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
34. **F** Takeuchi T, Thorne C, Karpouzas G, *et al.*: **Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.** *Ann Rheum Dis*. 2017; **76**(12): 2001–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
35. **F** Taylor PC, Schiff MH, Wang Q, *et al.*: **Efficacy and safety of monotherapy with sirukumab compared with active rheumatoid monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.** *Ann Rheum Dis*. 2018; **77**(5): 658–66. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
36. **F** Klatzmann D, Abbas AK: **The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.** *Nat Rev Immunol*. 2015; **15**(5): 283–94. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
37. **F** Rosenzweig M, Lorenzon R, Cacoub P, *et al.*: **Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.** *Ann Rheum Dis*. 2019; **78**(2): 209–17. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
38. Tchao N, Gorski KS, Yuraszek T, *et al.*: **Amg 592 Is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells.** *Blood*. 2017; **130**(Suppl 1): 696. [Reference Source](#)
39. Saxena A, Khosravi S, Noel S, *et al.*: **Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.** *Cytokine*. 2015; **74**(1): 27–34. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Galeazzi M, Bazzichi L, Sebastiani GD, *et al.*: **A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory 'armed antibody' for the treatment of rheumatoid arthritis, used in combination with methotrexate.** *Isr Med Assoc J*. 2014; **16**(10): 666. [PubMed Abstract](#)
41. Verma R, Balakrishnan L, Sharma K, *et al.*: **A network map of Interleukin-10 signaling pathway.** *J Cell Commun Signal*. 2016; **10**(1): 61–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Maini RNPH, Breedveld PC: **Hu IL-10 in subjects with active rheumatoid arthritis (I&A): phase I and cytokine response study.** *Arthritis Rheum*; Abstract Supplement of National Scientific Meeting; Washington, 1997; 224.
43. Galeazzi M, Sebastiani G, Voll R, *et al.*: **Dekavil (F8IL10) – update on the results of clinical trials investigating the immunocytokine in patients with rheumatoid arthritis.** *Ann Rheum Dis* 2018; **77**(2): 603–604. [Publisher Full Text](#)
44. Nanki T, Imai T, Kawai S: **Fractalkine/CX3CL1 in rheumatoid arthritis.** *Mod Rheumatol*. 2017; **27**(3): 392–7. [PubMed Abstract](#) | [Publisher Full Text](#)
45. Tanaka Y, Takeuchi T, Yamanaka H, *et al.*: **OP0223 EFFICACY AND SAFETY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN MTX-IR PATIENTS WITH RHEUMATOID ARTHRITIS.** *Ann Rheum Dis*. 2019; **78**(Suppl 2): 188. [Publisher Full Text](#)
46. **F** Ridgley LA, Anderson AE, Pratt AG: **What are the dominant cytokines in early rheumatoid arthritis?** *Curr Opin Rheumatol*. 2018; **30**(2): 207–14. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
47. Cavalli G, Dinarello CA: **Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.** *Rheumatology (Oxford)*. 2015; **54**(12): 2134–44. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Baslund B, Tvede N, Danneskiold-Samsøe B, *et al.*: **Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.** *Arthritis Rheum*. 2005; **52**(9): 2686–92. [PubMed Abstract](#) | [Publisher Full Text](#)
49. **F** Bridgewood C, Watad A, Cuthbert RJ, *et al.*: **Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics.** *Curr Opin Rheumatol*. 2018; **30**(5): 526–32. [PubMed Abstract](#) | [F1000 Recommendation](#)
50. **F** Baker KF, Isaacs JD: **Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?** *Ann Rheum Dis*. 2018; **77**(2): 175–87. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
51. Kragstrup TW, Andersen T, Heftdal LD, *et al.*: **The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis.** *Front Immunol*. 2018; **9**: 2226. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Šenolt L, Leszczynski P, Dokoupilová E, *et al.*: **Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial.** *Arthritis Rheumatol*. 2015; **67**(6): 1438–48. [PubMed Abstract](#) | [Publisher Full Text](#)
53. Yellin M, Paliienko I, Balanescu A, *et al.*: **A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.** *Arthritis Rheum*. 2012; **64**(6): 1730–9. [PubMed Abstract](#) | [Publisher Full Text](#)
54. **F** Du FH, Mills EA, Mao-Draayer Y: **Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment.** *Auto Immun Highlights*. 2017; **8**(1): 12. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
55. Damjanov N, Tlustochowicz M, Aelion J, *et al.*: **Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study.** *J Rheumatol*. 2016; **43**(12): 2094–100. [PubMed Abstract](#) | [Publisher Full Text](#)
56. Genovese MC, Fleischmann RM, Greenwald M, *et al.*: **Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.** *Ann Rheum Dis*. 2013; **72**(9): 1461–8. [PubMed Abstract](#) | [Publisher Full Text](#)
57. Hepburn TW, Totoritis MC, Davis CB: **Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.** *Rheumatology (Oxford)*. 2003; **42**(1): 54–61. [PubMed Abstract](#) | [Publisher Full Text](#)
58. **F** van Vollenhoven RF, Keystone EC, Strand V, *et al.*: **Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.** *Ann Rheum Dis*. 2018; **77**(4): 495–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
59. Finch R, Sostelly A, Sue-Ling K, *et al.*: **OP0224 RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY.** *Ann Rheum Dis*. 2019; **78**(Suppl 2): 189. [Publisher Full Text](#)
60. **F** Schmid AS, Neri D: **Advances in antibody engineering for rheumatic diseases.** *Nat Rev Rheumatol*. 2019; **15**(4): 197–207. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
61. Stealand S, Vandenbroucke RE, Libert C: **Nanobodies as therapeutics: big opportunities for small antibodies.** *Drug Discov Today*. 2016; **21**(7): 1076–113. [PubMed Abstract](#) | [Publisher Full Text](#)
62. Kontermann R: **Dual targeting strategies with bispecific antibodies.** *MAbs*. 2012; **4**(2): 182–97. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. **F** Neri D: **Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.** *Cancer Immunol Res*. 2019; **7**(3): 348–54. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
64. Fleischmann R, De Bruyn S, Duby C, *et al.*: **A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis on a Background of Methotrexate.** *Arthritis Rheumatol*. ACR meeting, abstract number 1311. 2012. [Reference Source](#)
65. Holz JB, Sargentini-Maier L, de Bruyn S, *et al.*: **OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/II Study in RA.** *Ann Rheum Dis*. 2014; **72**(Suppl 3): A64.1–A64. [Publisher Full Text](#)
66. Dörner T, Weinblatt M, Beneden KV, *et al.*: **Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.** *Ann Rheum Dis*. 2017; **76**(Suppl 2): 575. [Publisher Full Text](#)
67. Fischer JA, Hueber AJ, Wilson S, *et al.*: **Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: Development and characterization of a novel bispecific antibody.** *Arthritis Rheumatol*. 2015; **67**(1): 51–62. [PubMed Abstract](#) | [Publisher Full Text](#)
68. **F** Khatri A, Klünder B, Peloso PM, *et al.*: **Exposure-response analyses**

- demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis. *Rheumatology (Oxford)*. 2019; **58**(2): 352–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
69. **F** Kloppenburg M, Peterfy C, Haugen IK, *et al.*: Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1 α and anti-interleukin-1 β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. *Ann Rheum Dis*. 2019; **78**(3): 413–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 70. **F** Fleischmann RM, Bliddal H, Blanco FJ, *et al.*: A Phase II Trial of Lutikizumab, an Anti-Interleukin-1 α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. *Arthritis Rheumatol*. 2019; **71**(7): 1056–1069.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 71. **F** Cheung TT, McInnes IB: Future therapeutic targets in rheumatoid arthritis? *Semin Immunopathol*. 2017; **39**(4): 487–500.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 72. **F** Virtanen A, Haikarainen T, Raivola J, *et al.*: Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. *BioDrugs*. 2019; **33**(1): 15–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 73. Dörner T, Strand V, Cornes P, *et al.*: The changing landscape of biosimilars in rheumatology. *Ann Rheum Dis*. 2016; **75**(6): 974–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 74. **F** Aletaha D, Smolen JS: Diagnosis and Management of Rheumatoid Arthritis: A Review. *JAMA*. 2018; **320**(13): 1360–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 75. **F** Koopman FA, Maanen MA, Vervoordeldonk MJ, *et al.*: Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis. *J Intern Med*. 2017; **282**(1): 64–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 76. **F** Frank-Bertoncelj M, Klein K, Gay S: Interplay between genetic and epigenetic mechanisms in rheumatoid arthritis. *Epigenomics*. 2017; **9**(4): 493–504.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 77. Filková M, Jüngel A, Gay RE, *et al.*: MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy. *BioDrugs*. 2012; **26**(3): 131–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. van Vollenhoven RF, Nagy G, Tak PP: Early start and stop of biologics: has the time come? *BMC Med*. 2014; **12**: 25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 79. van Steenberg HW, da Silva JAP, Huizinga TWJ, *et al.*: Preventing progression from arthralgia to arthritis: targeting the right patients. *Nat Rev Rheumatol*. 2018; **14**(1): 32–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 80. **F** Hilliquin S, Hugues B, Mitrovic S, *et al.*: Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. *Ann Rheum Dis*. 2018; **77**(8): 1099–1106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 81. **F** Gerlag DM, Safy M, Maijer KI, *et al.*: Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. *Ann Rheum Dis*. 2019; **78**(2): 179–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 82. **F** Pozsgay J, Szekanecz Z, Sármy G: Antigen-specific immunotherapies in rheumatic diseases. *Nat Rev Rheumatol*. 2017; **13**(9): 525–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 83. **F** Pfeifle R, Rothe T, Ipseiz N, *et al.*: Regulation of autoantibody activity by the IL-23-T_H17 axis determines the onset of autoimmune disease. *Nat Immunol*. 2017; **18**(1): 104–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **John Isaacs**

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Competing Interests: No competing interests were disclosed.

2. **Diego Kyburz**

Experimental Rheumatology, University Hospital Basel, Basel, Switzerland

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research